Lineage Cell Therapeutics (NYSE:LCTX) shares tumbled 20% after pricing an offering to raise up to $66M.
The biotech entered into definitive agreements with certain investors and Broadwood Partners, an affiliate of its board member Neal Bradsher, for the purchase and sale of up to 39.47M common shares and accompanying warrants to purchase 39.47M shares at a combined price of $0.76 a share and accompanying warrant.
Each warrant will be exercisable at a price of $0.91 per common share. The potential gross proceeds to Lineage from the warrants, if fully exercised on a cash basis, will be ~$36M.
Lineage (LCTX) expects to receive $24M in aggregate gross proceeds from the offering with respect to the investments by the unaffiliated institutional investors, and around $6M from the offering with respect to the investment by Broadwood.
It currently plans to use the net proceeds from the offering for working capital and general corporate purposes, including research and development expenses and capital expenditures.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。